Figure 4 | British Journal of Cancer

Figure 4

From: Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer

Figure 4The alternative text for this image may have been generated using AI.

Apoptotic CTCs are less effectively captured by CEK or CPK methods. SKBR3 (HER2+ breast cancer) or HCC827 (EGFR mutant NSCLC) cells treated with vehicle or tyrosine kinase inhibitor (SKBR3: 1 μM lapatinib and HCC827; 1 μM gefitinib) for 24 h and processed with (A) CEK method. (B) CPK method or (C) smeared directly on slide without processing. Plots depict percentage of cells (±1 s.d.) staining for Ki67 (open bars, proliferation marker) or TUNEL (closed bars, apoptosis marker) by immunohistochemistry. (D) Percentage of CPK-processed CTCs from patients with NSCLC staining positive for KI67 and TUNEL. (E) Comparison of KI67 expression in CTCs recovered by CEK or CPK methods.

Back to article page